ArticleClinical and experimental immunology2014
Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.
Article in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Innate immunity and early liver inflammation.Frontiers in immunology · 2023Review
- Immunomodulation, Toxicity, and Therapeutic Potential of Nanoparticles.Biotech (Basel (Switzerland)) · 2022Review
- Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma.The Journal of experimental medicine · 2021Article
- Interleukin-30 Suppresses Not Only CD4Biomedicines · 2021Article
- Rodent models of cholestatic liver disease: A practical guide for translational research.Liver international : official journal of the International Association for the Study of the Liver · 2021Review
- Animal Models of Autoimmune Liver Diseases: a Comprehensive Review.Clinical reviews in allergy & immunology · 2020Review
- The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?Canadian journal of gastroenterology & hepatology · 2018Review
- Galectin-3 regulates inflammasome activation in cholestatic liver injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Dual Roles of IFN-γ and IL-4 in the Natural History of Murine Autoimmune Cholangitis: IL-30 and Implications for Precision Medicine.Scientific reports · 2016Article
- Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance.Hepatology (Baltimore, Md.) · 2016Article
- A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.Expert review of molecular diagnostics · 2016Review
- Adaptive immunity in the liver.Cellular & molecular immunology · 2016Review
- Xenobiotics and loss of tolerance in primary biliary cholangitis.World journal of gastroenterology · 2016Review
- AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis.Journal of autoimmunity · 2016Article
- Unmet challenges in immune-mediated hepatobiliary diseases.Clinical reviews in allergy & immunology · 2015Article
- Animal models of primary biliary cirrhosis.Clinical reviews in allergy & immunology · 2015Review
- The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.Clinical reviews in allergy & immunology · 2015Review
- Novel therapeutic targets in primary biliary cirrhosis.Nature reviews. Gastroenterology & hepatology · 2015Review
- Innate immunity drives the initiation of a murine model of primary biliary cirrhosis.PloS one · 2015Article
- Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.Clinical and experimental immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Although primary biliary cirrhosis (PBC) is considered a model autoimmune disease, it has not responded therapeutically to traditional immunosuppressive agents. In addition, PBC may recur following liver transplantation, despite the absence of major histocompatibility complex (MHC) matching, in sharp contrast to the well-known paradigm of MHC restriction. We have suggested previously that invariant natural killer T (iNK T) cells are critical to the initiation of PBC. In this study we have taken advantage of our ability to induce autoimmune cholangitis with 2-octynoic acid, a common component of cosmetics, conjugated to bovine serum albumin (2-OA-BSA), and studied the natural history of pathology in mice genetically deleted for CD4 or CD8 following immunization with 2-OA-BSA in the presence or absence of α-galactosylceramide (α-GalCer). In particular, we address whether autoimmune cholangitis can be induced in the absence of traditional CD4 and CD8 responses. We report herein that CD4 and CD8 knock-out mice immunized with 2-OA-BSA/PBS or 2-OA-BSA/α-GalCer develop anti-mitochondrial antibodies (AMAs), portal infiltrates and fibrosis. Indeed, our data suggest that the innate immunity is critical for immunopathology and that the pathology is exacerbated in the presence of α-GalCer. In conclusion, these data provide not only an explanation for the recurrence of PBC following liver transplantation in the absence of MHC compatibility, but also suggest that effective therapies for PBC must include blocking of both innate and adaptive pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.